Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Cardiovascular disease (CVD) is the leading cause of global morbidity and mortality, with its prevalence increasing significantly from 1990 to 2019. Establishing a comprehensive cardiac surgery database is crucial for exploring perioperative prognostic factors and improving clinical outcomes.
This muti-center, prospective observational study aims to construct a prospective cohort database for perioperative cardiac surgery. We plan to enroll adult patients who undergo cardiac surgery with cardiopulmonary bypass at the Second Affiliated Hospital of Zhejiang University and other hospitals from May 1, 2026 to December 31, 2031. Multi-dimensional perioperative data, including laboratory tests, hemodynamics, intraoperative echocardiography, and perioperative medications, will be collected and integrated, along with epidemiological data, clinical diagnosis and treatment information, multimodal data, and follow-up outcomes. An interconnected big data sharing platform will also be built.
This database will provide a valuable resource for multi-level researches such as perioperative risk assessment, individualized prevention, precise diagnosis and treatment, and therapeutic efficacy monitoring. It will also help optimize surgical and perioperative management, improve the quality of cardiac surgery, and provide evidence for the refinement of China's healthcare system, ultimately enhancing perioperative safety and rehabilitation efficiency of patients.
1. Establish a cohort of perioperative surgical patients across multiple medical centers, tracking them from enrollment through 1 year post-surgery, and build a database of data relevant to patient outcomes; 2. Investigate the impact of preoperative psychological and physical factors on short-term postoperative complications in surgical patients, develop predictive models, and conduct prospective validation; 3. Investigate the impact of preoperative psychological, physical, and social factors on long-term postoperative complications; 4. Investigate the incidence of acute and chronic postoperative pain, associated risk factors, and their impact on prognosis; 5. Investigate the optimal perioperative transfusion strategies for allogeneic blood products based on causal relationships, develop predictive models, and validate them.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Perioperative Observation Group | Patients undergoing cardiac surgery with cardiopulmonary bypass during the perioperative period (including, but not limited to, valve surgery, coronary artery bypass grafting, and combined procedures that require cardiopulmonary bypass) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cardiac surgey | Procedure | Cardiac surgey |
|
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of major adverse cardiac and cerebrovascular events (MACCE) | Myocardial infarction; New-onset stroke: new irreversible neurological impairment confirmed by radiological examination or autopsy showing a new cerebral lesion; Death | 4, 12 weeks and 1years after surgery |
| Incidence of Perioperative Transfusion of Allogeneic Blood Products | Allogeneic red blood cells, plasma, platelets, and blood coagulation factors | 30 days after surgery |
| Amount of Allogeneic Blood Products Transfused During the Perioperative Period | Allogeneic red blood cells, plasma, platelets, and blood coagulation factors | 30 days after surgery |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of perioperative myocardial infarction | Myocardial infarction | 4, 12 weeks and 1years after surgery |
| Incidence of New-onset stroke | New-onset stroke: new irreversible neurological impairment confirmed by radiological examination or autopsy showing a new cerebral lesion |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients undergoing cardiac surgery from May 1, 2026 to December 31, 2031
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Min Yan, Doctor | Contact | 15888210247 | zryanmin@zju.edu.cn |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China | Recruiting | Hangzhou | Zhejiang | China |
Not provided
| ID | Term |
|---|---|
| D006349 | Heart Valve Diseases |
| D003324 | Coronary Artery Disease |
| D003327 | Coronary Disease |
| D001018 | Aortic Diseases |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D017202 | Myocardial Ischemia |
| D001161 | Arteriosclerosis |
Not provided
Not provided
Not provided
Not provided
Not provided
| 4, 12 weeks and 1years after surgery |
| Incidence of death | death | 4, 12 weeks and 1years after surgery |
| Incidence of acute kidney injury | acute kidney injury was defined by guidelines of kindey disease：improving global outcomes（KIDGO） | 7days after suegery |
| Incidence of infectious complications | Infectious complications include, but are not limited to, pneumonia, surgical site infection, etc. | 4, 12 weeks and 1years after surgery |
| Incidence of unplanned hospital readmission within 4 and 12 weeks after surgery | Unplanned hospital readmission | 4 and 12 weeks after surgery |
| Length of hospital stay | Length of hospital stay | Through patients discharge, an average of 7 days after surgery |
| Hospitalization costs | Hospitalization costs | Through patients discharge, an average of 7 days after surgery |
| Quality of life scores | Quality of life was assessed using the EuroQol Five-Dimensional Questionnaire (EQ-5D) EuroQol Five-Dimensional Questionnaire (EQ-5D): The EQ-5D includes a visual analog scale (EQ-VAS) ranging from 0 to 100, where higher scores indicate better health status. | at 4, 12 weeks and 1 years after surgery |
| Quality of life scores | Quality of life was assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ). Kansas City Cardiomyopathy Questionnaire (KCCQ): The KCCQ consists of 23 items that quantify the following domains: physical limitations, symptoms (including symptom frequency, severity, and change over time), self-efficacy, social function, and quality of life. The total score ranges from 0 to 100, with higher scores representing better quality of life. | at 4, 12 weeks and 1 years after surgery |
| D001157 |
| Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |